BSE Live
Apr 02, 16:01Prev. Close
73.11
Open Price
74.92
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 02, 15:53Prev. Close
72.98
Open Price
72.00
Bid Price (Qty.)
73.81 (1)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Anuh Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | |
| Diluted EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | |
| Cash EPS (Rs.) | 11.19 | 13.70 | 9.16 | 8.49 | 8.68 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 | |
| Dividend / Share(Rs.) | 1.50 | 2.50 | 2.00 | 1.75 | 1.50 | |
| Revenue from Operations/Share (Rs.) | 132.01 | 129.11 | 105.26 | 97.11 | 86.20 | |
| PBDIT/Share (Rs.) | 14.04 | 17.41 | 11.45 | 10.39 | 11.00 | |
| PBIT/Share (Rs.) | 12.30 | 15.70 | 9.52 | 8.00 | 7.99 | |
| PBT/Share (Rs.) | 12.17 | 15.63 | 9.47 | 7.81 | 7.69 | |
| Net Profit/Share (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 10.63 | 13.48 | 10.87 | 10.69 | 12.76 | |
| PBIT Margin (%) | 9.31 | 12.15 | 9.04 | 8.23 | 9.27 | |
| PBT Margin (%) | 9.22 | 12.10 | 8.99 | 8.03 | 8.92 | |
| Net Profit Margin (%) | 7.15 | 9.28 | 6.85 | 6.27 | 6.58 | |
| Return on Networth / Equity (%) | 14.52 | 20.62 | 14.99 | 14.29 | 14.91 | |
| Return on Capital Employed (%) | 18.78 | 26.84 | 19.57 | 18.53 | 20.73 | |
| Return on Assets (%) | 9.34 | 13.47 | 8.93 | 8.80 | 8.54 | |
| Total Debt/Equity (X) | 0.03 | 0.01 | 0.00 | 0.01 | 0.07 | |
| Asset Turnover Ratio (%) | 1.39 | 1.52 | 1.40 | 1.43 | 1.31 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.11 | 2.20 | 1.91 | 1.98 | 1.70 | |
| Quick Ratio (X) | 1.69 | 1.71 | 1.46 | 1.37 | 1.12 | |
| Inventory Turnover Ratio (X) | 8.83 | 8.74 | 4.94 | 4.36 | 4.53 | |
| Dividend Payout Ratio (NP) (%) | 26.45 | 16.68 | 24.23 | 24.59 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 22.33 | 14.60 | 19.11 | 17.67 | 0.00 | |
| Earnings Retention Ratio (%) | 73.55 | 83.32 | 75.77 | 75.41 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 77.67 | 85.40 | 80.89 | 82.33 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 736.68 | 1,223.09 | 392.34 | 417.88 | 446.02 | |
| EV/Net Operating Revenue (X) | 1.11 | 1.89 | 0.74 | 0.86 | 1.03 | |
| EV/EBITDA (X) | 10.47 | 14.02 | 6.84 | 8.03 | 8.09 | |
| MarketCap/Net Operating Revenue (X) | 1.13 | 1.90 | 0.76 | 0.89 | 1.05 | |
| Retention Ratios (%) | 73.54 | 83.31 | 75.76 | 75.40 | 0.00 | |
| Price/BV (X) | 2.29 | 4.23 | 1.65 | 2.01 | 2.37 | |
| Price/Net Operating Revenue | 1.13 | 1.90 | 0.76 | 0.89 | 1.05 | |
| Earnings Yield | 0.06 | 0.05 | 0.09 | 0.07 | 0.06 |
10.02.2026
Anuh Pharma Standalone December 2025 Net Sales at Rs 197.18 crore, up 23.61% Y-o-Y
12.11.2025
Anuh Pharma Standalone September 2025 Net Sales at Rs 185.88 crore, up 12.01% Y-o-Y
22.08.2025
Anuh Pharma Standalone June 2025 Net Sales at Rs 186.48 crore, up 35.22% Y-o-Y
27.05.2025
Anuh Pharma Standalone March 2025 Net Sales at Rs 198.14 crore, up 20.9% Y-o-Y
10.02.2026
Anuh Pharma Standalone December 2025 Net Sales at Rs 197.18 crore, up 23.61% Y-o-Y
12.11.2025
Anuh Pharma Standalone September 2025 Net Sales at Rs 185.88 crore, up 12.01% Y-o-Y
22.08.2025
Anuh Pharma Standalone June 2025 Net Sales at Rs 186.48 crore, up 35.22% Y-o-Y
27.05.2025
Anuh Pharma Standalone March 2025 Net Sales at Rs 198.14 crore, up 20.9% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth